Updated review of therapeutic strategies for Charcot-Marie-Tooth disease and related neuropathies

References

• Pareyson D, Saveri P, Pisciotta C. New developments in Charcot-Marie-Tooth neuropathy and related diseases. Curr Opin Neurol. 2017;30:471–480.
   PubMed Web of Science ®Google Scholar
• Pisciotta C, Shy ME. Neuropathy. Handb Clin Neurol. 2018;148:653–665.
   PubMedGoogle Scholar
• Nobbio L, Visigalli D, Radice D, et al. PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker. Brain. 2014;137:1614–1620.
   PubMed Web of Science ®Google Scholar
• Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med. 2004;10:396–401.
   PubMed Web of Science ®Google Scholar
• Gess B, Baets J, De Jonghe P, et al. Ascorbic acid for the treatment of Charcot-Marie-Tooth disease. Cochrane Database Syst Rev. 2015;12:CD011952.
   PubMed Web of Science ®Google Scholar
• Pareyson D, Reilly MM, Schenone A, et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol. 2011;10:320–328.
   PubMed Web of Science ®Google Scholar
• Meyer Zu Horste G, Prukop T, Liebetanz D, et al. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol. 2007;61:61–72.
   PubMed Web of Science ®Google Scholar
• Corell M, Wicher G, Radomska KJ, et al. GABA and its B-receptor are present at the node of Ranvier in a small population of sensory fibers, implicating a role in myelination. J Neurosci Res. 2015;93:285–295.
   PubMed Web of Science ®Google Scholar
• Chumakov I, Milet A, Cholet N, et al. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet J Rare Dis. 2014;9:201.
   PubMed Web of Science ®Google Scholar
• Prukop T, Stenzel J, Wernick S, et al. Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A). PLoS One. 2019;14:e0209752.
   PubMed Web of Science ®Google Scholar
• Attarian S, Vallat JM, Magy L, et al. An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet J Rare Dis. 2014;9:199.
   PubMed Web of Science ®Google Scholar
• Piscosquito G, Reilly MM, Schenone A, et al. Responsiveness of clinical outcome measures in Charcot-Marie-Tooth disease. Eur J Neurol. 2015;22:1556–1563.
   PubMed Web of Science ®Google Scholar
• Zhao HT, Damle S, Ikeda-Lee K, et al. PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. J Clin Invest. 2018;128:359–368.
   PubMed Web of Science ®Google Scholar
• Boutary S, Caillaud M, El Madani M, et al. Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1A. Commun Biol. 2021;4:317.
   PubMed Web of Science ®Google Scholar
• Lee JS, Lee JY, Song DW, et al. Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice. Nucleic Acids Res. 2020;48:130–140.
   PubMed Web of Science ®Google Scholar
• Gautier B, Hajjar H, Soares S, et al. AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A. Nat Commun. 2021;12:2356.
   PubMed Web of Science ®Google Scholar
• Lee JS, Chang EH, Koo OJ, et al. Pmp22 mutant allele-specific siRNA alleviates demyelinating neuropathic phenotype in vivo. Neurobiol Dis. 2017;100:99–107.
   PubMed Web of Science ®Google Scholar
• Sahenk Z, Nagaraja HN, McCracken BS, et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology. 2005;65:681–689.
   PubMed Web of Science ®Google Scholar
• Sahenk Z, Galloway G, Clark KR, et al. AAV1.NT-3 gene therapy for charcot-marie-tooth neuropathy. Mol Ther. 2014;22:511–521.
   PubMed Web of Science ®Google Scholar
• Yalvac ME, Amornvit J, Chen L, et al. AAV1.NT-3 gene therapy increases muscle fiber diameter through activation of mTOR pathway and metabolic remodeling in a CMT mouse model. Gene Ther. 2018;25:129–138.
   PubMed Web of Science ®Google Scholar
• Ozes B, Myers M, Moss K, et al. AAV1.NT-3 gene therapy for X-linked Charcot-Marie-Tooth neuropathy type 1. Gene Ther. 2021 Feb 4.
   PubMed Web of Science ®Google Scholar
• Sargiannidou I, Kagiava A, Bashiardes S, et al. Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease. Ann Neurol. 2015;78:303–316.
   PubMed Web of Science ®Google Scholar
• Kagiava A, Karaiskos C, Richter J, et al. Intrathecal gene therapy in mouse models expressing CMT1X mutations. Hum Mol Genet. 2018;27:1460–1473.
   PubMed Web of Science ®Google Scholar
• Kagiava A, Karaiskos C, Richter J, et al. AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy. Gene Ther. 2021 Mar;10.
   Web of Science ®Google Scholar
• Schiza N, Georgiou E, Kagiava A, et al. Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy. Brain. 2019;142:1227–1241.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Carmona S, Muhammad AKMG, et al. Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model. J Clin Invest. 2019;129:1756–1771.
   PubMed Web of Science ®Google Scholar
• Rocha AG, Franco A, Krezel AM, et al. MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. Science. 2018;360:336–341.
   PubMed Web of Science ®Google Scholar
• Fledrich R, Abdelaal T, Rasch L, et al. Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy. Nat Commun. 2018;9:3025.
   PubMed Web of Science ®Google Scholar
• Nobbio L, Sturla L, Fiorese F, et al. P2X7-mediated increased intracellular calcium causes functional derangement in Schwann cells from rats with CMT1A neuropathy. J Biol Chem. 2009;284:23146–23158.
   PubMed Web of Science ®Google Scholar
• Sociali G, Visigalli D, Prukop T, et al. Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy. Neurobiol Dis. 2016;95:145–157.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Wang MM, Layton M, et al. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis. 2012;71:1630–1635.
   PubMed Web of Science ®Google Scholar
• Bai Y, Wu X, Brennan KM, et al. Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B. Ann Clin Transl Neurol. 2018;5:445–455.
   PubMed Web of Science ®Google Scholar
• Khajavi M, Inoue K, Wiszniewski W, et al. Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants. Am J Hum Genet. 2005;77:841–850.
   PubMed Web of Science ®Google Scholar
• Patzkó A, Bai Y, Saporta MA, et al. Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice. Brain. 2012;135:3551–3566.
   PubMed Web of Science ®Google Scholar
• Das I, Krzyzosiak A, Schneider K, et al. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science. 2015;348:239–242.
   PubMed Web of Science ®Google Scholar
• Bai Y, LaMarche M, Wang D, et al. Treatment of Arg98Cys MPZ Mice In Vitro and In Vivo with IFB088. Presented at the PNS 2019 Annual Meeting. Genoa, Italy. 22-25 June.
   Google Scholar
• Khajavi M, Shiga K, Wiszniewski W, et al. Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy. Am J Hum Genet. 2007;81:438–453.
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Pehlivan D, Wiszniewski W, et al. Curcumin facilitates a transitory cellular stress response in Trembler-J mice. Hum Mol Genet. 2013;22:4698–4705.
   PubMed Web of Science ®Google Scholar
• Fortun J, Go JC, Li J, et al. Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression. Neurobiol Dis. 2006;22:153–164.
   PubMed Web of Science ®Google Scholar
• Lee S, Bazick H, Chittoor-Vinod V, et al. Elevated peripheral myelin protein 22, reduced mitotic potential, and proteasome impairment in dermal fibroblasts from Charcot-Marie-Tooth Disease Type 1A Patients. Am J Pathol. 2018;188:728–738.
   PubMed Web of Science ®Google Scholar
• D’Antonio M, Treins C, Scapin C, et al. IFB-088 treatment improves Charcot-Marie-Tooth type 1A disease phenotype of C3-PMP22 mice. Presented at the PNS 2019 Annual Meeting. Genoa, Italy. 22-25 June.
   Google Scholar
• Rosberg MR, Alvarez S, Krarup C, et al. An oral NaV1.8 blocker improves motor function in mice completely deficient of myelin protein P0. Neurosci Lett. 2016;632:33–38.
   PubMed Web of Science ®Google Scholar
• Moldovan M, Pisciotta C, Pareyson D, et al. Myelin protein zero gene dose dependent axonal ion-channel dysfunction in a family with Charcot-Marie-Tooth disease. Clin Neurophysiol. 2020;131:2440–2451.
   PubMed Web of Science ®Google Scholar
• Taveggia C, Zanazzi G, Petrylak A, et al. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron. 2005;47:681–694.
   PubMed Web of Science ®Google Scholar
• Bolino A, Piguet F, Alberizzi V, et al. Niacin-mediated Tace activation ameliorates CMT neuropathies with focal hypermyelination. EMBO Mol Med. 2016;8:1438–1454.
   PubMed Web of Science ®Google Scholar
• Scapin C, Ferri C, Pettinato E, et al. Enhanced axonal neuregulin-1 type-III signaling ameliorates neurophysiology and hypomyelination in a Charcot-Marie-Tooth type 1B mouse model. Hum Mol Genet. 2019;28:992–1006.
   PubMed Web of Science ®Google Scholar
• Fledrich R, Stassart RM, Klink A, et al. Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A. Nat Med. 2014;20:1055–1061.
   PubMed Web of Science ®Google Scholar
• Pareyson D, Stojkovic T, Reilly MM, et al. A multicenter retrospective study of Charcot-Marie-Tooth disease type 4B (CMT4B) associated with mutations in myotubularin-related proteins (MTMRs). Ann Neurol. 2019;86:55–67.
   PubMed Web of Science ®Google Scholar
• Guerrero-Valero M, Grandi F, Cipriani S, et al. Dysregulation of myelin synthesis and actomyosin function underlies aberrant myelin in CMT4B1 neuropathy. Proc Natl Acad Sci U S A. 2021;118:e2009469118.
   PubMed Web of Science ®Google Scholar
• Geisler S, Huang SX, Strickland A, et al. Gene therapy targeting SARM1 blocks pathological axon degeneration in mice. J Exp Med. 2019;216:294–303.
   PubMed Web of Science ®Google Scholar
• d’Ydewalle C, Krishnan J, Chiheb DM, et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med. 2011;17:968–974.
   PubMed Web of Science ®Google Scholar
• Benoy V, Van Helleputte L, Prior R, et al. HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease. Brain. 2018;141:673–687.
   PubMed Web of Science ®Google Scholar
• Picci C, Wong VSC, Costa CJ, et al. HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice. Exp Neurol. 2020;328:113281.
   PubMed Web of Science ®Google Scholar
• Glasser CE, Gartner MR, Wilson D, et al. Locally acting ACE-083 increases muscle volume in healthy volunteers. Muscle Nerve. 2018;57:921–926.
   PubMed Web of Science ®Google Scholar
• Klein D, Patzkó Á, Schreiber D, et al. Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice. Brain. 2015;138:3193–3205.
   PubMed Web of Science ®Google Scholar
• Cortese A, Zhu Y, Rebelo AP, et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet. 2020;52:473–481.
   PubMed Web of Science ®Google Scholar
• Fridman V, Suriyanarayanan S, Novak P, et al. Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1. Neurology. 2019;92:e359–e370.
   PubMed Web of Science ®Google Scholar
• Kugathasan U, Evans MRB, Morrow JM, et al. Development of MRC Centre MRI calf muscle fat fraction protocol as a sensitive outcome measure in hereditary sensory neuropathy Type 1. J Neurol Neurosurg Psychiatry. 2019;90:895–906.
   PubMed Web of Science ®Google Scholar
• de Brouwer AP, van Bokhoven H, Nabuurs SB, et al. PRPS1 mutations: four distinct syndromes and potential treatment. Am J Hum Genet. 2010;86:506–518.
   PubMed Web of Science ®Google Scholar
• Perez-Siles G, Cutrupi A, Ellis M, et al. Energy metabolism and mitochondrial defects in X-linked Charcot-Marie-Tooth (CMTX6) iPSC-derived motor neurons with the p.R158H PDK3 mutation. Sci Rep. 2020;10:9262.
   PubMed Web of Science ®Google Scholar
• Juneja M, Burns J, Saporta MA, et al. Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development. J Neurol Neurosurg Psychiatry. 2019;90:58–67.
   PubMed Web of Science ®Google Scholar
• Svaren J, Moran JJ, Wu X, et al. Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies. Ann Neurol. 2019;85:887–898.
   PubMed Web of Science ®Google Scholar
• Tucker-Bartley A, Lemme J, Gomez-Morad A, et al. Pain phenotypes in rare musculoskeletal and neuromuscular diseases. Neurosci Biobehav Rev. 2021;124:267–290.
   PubMed Web of Science ®Google Scholar
• Sman AD, Hackett D, Fiatarone Singh M, et al. Systematic review of exercise for Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2015;20:347–362.
   PubMed Web of Science ®Google Scholar
• Corrado B, Ciardi G, Bargigli C. Rehabilitation Management of the Charcot-Marie-Tooth syndrome: a systematic review of the literature. Medicine (Baltimore). 2016;95:e3278.
   PubMed Web of Science ®Google Scholar
• Reilly MM, Pareyson D, Burns J, et al. 221st ENMC International Workshop: Foot Surgery in Charcot-Marie-Tooth disease. 10-12 June 2016, Naarden, The Netherlands. Neuromuscul Disord 2017; 27:1138–1142.
   Google Scholar
• Rossor AM, Shy ME, Reilly MM. Are we prepared for clinical trials in Charcot-Marie-Tooth disease? Brain Res. 2020;1729:146625.
   PubMed Web of Science ®Google Scholar
• Pipis M, Feely SME, Polke JM, et al. Natural history of Charcot- Marie-Tooth disease type 2A: a large international multicentre study. Brain. 2020;143:3589–3602.
   PubMed Web of Science ®Google Scholar
• Fridman V, Sillau S, Acsadi G, et al. A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores. Neurology. 2020;94:e884–e896.
   PubMed Web of Science ®Google Scholar
• Cornett KMD, Menezes MP, Shy RR, et al. Natural history of Charcot-Marie-Tooth disease during childhood. Ann Neurol. 2017;82:353–359.
   PubMed Web of Science ®Google Scholar
• Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2011;16:191–198.
   PubMed Web of Science ®Google Scholar
• Sadjadi R, Reilly MM, Shy ME, et al. Psychometrics evaluation of Charcot-Marie-Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis. J Peripher Nerv Syst. 2014;19:192–196.
   PubMed Web of Science ®Google Scholar
• Burns J, Ouvrier R, Estilow T, et al. Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability. Ann Neurol. 2012;71:642–652.
   PubMed Web of Science ®Google Scholar
• Eichinger K, Burns J, Cornett K, et al. The Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM). Neurology. 2018;91:e1381–e1384.
   PubMed Web of Science ®Google Scholar
• Bray P, Cornett KMD, Estilow T, et al. Reliability of the Charcot-Marie-Tooth functional outcome measure. J Peripher Nerv Syst. 2020;25:288–291.
   PubMed Web of Science ®Google Scholar
• Johnson NE, Heatwole C, Creigh P, et al. The Charcot-Marie-Tooth health index: evaluation of a patient-reported outcome. Ann Neurol. 2018;84:225–233.
   PubMed Web of Science ®Google Scholar
• Pisciotta C, Ciafaloni E, Zuccarino R, et al. Validation of the Italian version of the Charcot-Marie-Tooth health index. J Peripher Nerv Syst. 2020;25:292–296.
   PubMed Web of Science ®Google Scholar
• Ramchandren S, Wu TT, Finkel RS, et al. Development and validation of the pediatric Charcot-Marie-Tooth disease quality of life outcome measure. Ann Neurol. 2021;89:369–379.
   PubMed Web of Science ®Google Scholar
• Morrow JM, Evans MRB, Grider T, et al. Validation of MRC Centre MRI calf muscle fat fraction protocol as an outcome measure in CMT1A. Neurology. 2018;91:e1125–e1129.
   PubMed Web of Science ®Google Scholar
• Sandelius Å, Zetterberg H, Blennow K, et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018;90:e518–e524.
   PubMed Web of Science ®Google Scholar
• Schorling E, Thiele S, Gumbert L, et al. Cost of illness in Charcot-Marie-Tooth neuropathy: results from Germany. Neurology. 2019;92:e2027–e2037.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379:11–21.
   PubMed Web of Science ®Google Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379:22–31.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017;377:1723–1732.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Onasemnogene Abeparvovec: first global approval. Drugs. 2019;79:1255–1262.
   PubMed Web of Science ®Google Scholar
• Van Hameren G, Gonzalez S, Fernando RN, et al. In Vivo Introduction of transgenes into mouse sciatic nerve cells using viral vectors. Methods Mol Biol. 2018;1791:263–276.
   PubMedGoogle Scholar